AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21763217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood-stabilizing medications
Number of subjects: 140
Study 21763217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower scores on the 'powerful others' dimension of locus of control
Number of subjects: 140
Study 21763217 — intervention group
Group type: COMPARATOR
Intervention: BSRI masculinity scores
Number of subjects: 140
Study 21763653 — intervention group
Group type: EXPERIMENTAL
Intervention: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy (HmG-CoA-reductase inhibitors)
Number of subjects: 100
Study 21763653 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 100
Study 21763653 — intervention group
Group type: EXPERIMENTAL
Intervention: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy
Number of subjects: 100
Study 21764499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm analysis pause during CPR
Number of subjects: 5
Study 21764499 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of CPR before and after the pause
Number of subjects: 5
Study 21764815 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled in-hospital follow-up of CIEDs
Number of subjects: 3362
Study 21764815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 3362
Study 21764815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker (PM)
Number of subjects: 3362
Study 21764815 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 3362
Study 21764815 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled visits
Number of subjects: 3362
Study 21764815 — intervention group
Group type: EXPERIMENTAL
Intervention: First visits
Number of subjects: 3362
Study 21765003 — intervention group
Group type: EXPERIMENTAL
Intervention: Food record
Number of subjects: 450
Study 21765003 — intervention group
Group type: COMPARATOR
Intervention: Food frequency questionnaire
Number of subjects: 450
Study 21765003 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour dietary recalls
Number of subjects: 450
Study 21765003 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration equations including body mass index, age, and ethnicity
Number of subjects: 450
Study 21765072 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor questionnaire
Number of subjects: 0
Study 21765072 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON Gold In-Tube test
Number of subjects: 0
Study 21765072 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB test
Number of subjects: 0
Study 21765072 — intervention group
Group type: EXPERIMENTAL
Intervention: TST
Number of subjects: 0
Study 21765124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with copeptin concentrations in the highest quartile
Number of subjects: 557
Study 21765124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated copeptin and hyponatremia
Number of subjects: 557
Study 21765124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated copeptin
Number of subjects: 557
Study 21765124 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 557
Study 21765864 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with behavioral activation strategies (38 classes over 24 weeks)
Number of subjects: 60
Study 21765864 — intervention group
Group type: COMPARATOR
Intervention: Usual care (depression treatment referrals and print information on diabetes management)
Number of subjects: 60
Study 21767228 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected men
Number of subjects: 586
Study 21767228 — intervention group
Group type: COMPARATOR
Intervention: Control men
Number of subjects: 586
Study 21767228 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 586
Study 21767228 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 586
Study 21767228 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with greater visceral AT (VAT)
Number of subjects: 586
Study 21767228 — intervention group
Group type: COMPARATOR
Intervention: Control subjects in lowest quartile of leg SAT
Number of subjects: 586
Study 21767228 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with low leg SAT
Number of subjects: 586
Study 21767331 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Number of subjects: 3
Study 21767595 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-μg dose of a monovalent, unadjuvanted inactivated 2009 H1N1 influenza vaccine
Number of subjects: 148
Study 21768536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonapposed side-branch struts
Number of subjects: 99
Study 21768536 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA struts
Number of subjects: 99
Study 21768536 — intervention group
Group type: COMPARATOR
Intervention: Well-apposed struts
Number of subjects: 99
Study 21769849 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (up to 600 mg/day)
Number of subjects: 20
Study 21771823 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo CRT implantations
Number of subjects: 2367
Study 21771823 — intervention group
Group type: COMPARATOR
Intervention: Upgrades to CRT
Number of subjects: 2367
Study 21771823 — intervention group
Group type: COMPARATOR
Intervention: Both groups (de novo and upgrades)
Number of subjects: 2367
Study 21771924 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT
Number of subjects: 40
Study 21771924 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 21771945 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 1159
Study 21771945 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac troponin assay (cTnT)
Number of subjects: 1159
Study 21772051 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated tricuspid regurgitant jet velocity (TRV)
Number of subjects: 325
Study 21772051 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, splenectomy, hepatitis C, smoking
Number of subjects: 325
Study 21774578 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekends
Number of subjects: 81
Study 21774843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nit-Occlud® PDA-R
Number of subjects: 29
Study 21775114 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 0
Study 21775497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 539
Study 21775510 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant women (C-ISI <4.6)
Number of subjects: 65
Study 21775510 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive women
Number of subjects: 65
Study 21775510 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with impaired glucose tolerance
Number of subjects: 65
Study 21775510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (insulin-resistant and insulin-sensitive)
Number of subjects: 65
Study 21775836 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial endometriosis lesions
Number of subjects: 96
Study 21775836 — intervention group
Group type: EXPERIMENTAL
Intervention: Deeply infiltrating lesions
Number of subjects: 96
Study 21775836 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriomas
Number of subjects: 96
Study 21775836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion depth, disease burden, and number of lesions or endometriomas
Number of subjects: 96
Study 21775836 — intervention group
Group type: COMPARATOR
Intervention: Chronic pain patients without endometriosis (n = 37)
Number of subjects: 96
Study 21777076 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated HIV-infected children
Number of subjects: 294
Study 21777076 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 counts above WHO ART-initiation criteria (n=53)
Number of subjects: 294
Study 21777076 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 294
Study 21777890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) measurements
Number of subjects: 267
Study 21777890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) parameters
Number of subjects: 267
Study 21778120 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD) measured at baseline and annually
Number of subjects: 2110
Study 21778120 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD)
Number of subjects: 2110
Study 21778257 — intervention group
Group type: COMPARATOR
Intervention: Portopulmonary hypertension (PoPH)
Number of subjects: 174
Study 21778262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 12
Study 21778262 — intervention group
Group type: COMPARATOR
Intervention: Self-paced walking
Number of subjects: 12
Study 21782507 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 395
Study 21782507 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 395
Study 21782771 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Mallory-Denk bodies (MDBs) in liver biopsy samples
Number of subjects: 1050
Study 21782771 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MDBs
Number of subjects: 1050
Study 21782771 — intervention group
Group type: EXPERIMENTAL
Intervention: MDB gain (61 patients, 7.2%)
Number of subjects: 1050
Study 21782771 — intervention group
Group type: EXPERIMENTAL
Intervention: MDB loss (101 patients, 12.0%)
Number of subjects: 1050
Study 21782771 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of MDBs
Number of subjects: 1050
Study 21784508 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-4658 (phosphorodiamidate morpholino oligomer) at doses of 0.5, 1.0, 2.0, 4.0, 10.0, and 20.0 mg/kg bodyweight
Number of subjects: 19
Study 21784508 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-4658 (phosphorodiamidate morpholino oligomer)
Number of subjects: 19
Study 21784781 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution (AZLI) thrice daily (AZLI3)
Number of subjects: 274
Study 21785475 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy continued during interventional techniques
Number of subjects: 3179
Study 21785475 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic therapy discontinued prior to interventional techniques
Number of subjects: 3179
Study 21785475 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 3179
Study 21787417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day orally for 4 weeks on treatment, followed by 2 weeks off treatment
Number of subjects: 37
Study 21788422 — intervention group
Group type: EXPERIMENTAL
Intervention: ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada), 0.5-mL dose
Number of subjects: 138
Study 21788584 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-WSS segments
Number of subjects: 20
Study 21788584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-WSS segments
Number of subjects: 20
Study 21788584 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-WSS segments
Number of subjects: 20
Study 21789167 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely burned pediatric patients
Number of subjects: 977
Study 21789167 — intervention group
Group type: COMPARATOR
Intervention: Non-burned, non-injured children
Number of subjects: 977
Study 21789604 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected vaginal swabs
Number of subjects: 190
Study 21789604 — intervention group
Group type: COMPARATOR
Intervention: Practitioner-collected swabs
Number of subjects: 190
Study 21789604 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected swabs for high concentrations of A. vaginae (≥10^8 copies/mL)
Number of subjects: 190
Study 21789604 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected swabs for high concentrations of G. vaginalis (≥10^9 copies/mL)
Number of subjects: 190
Study 21791058 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 100 mg QD + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Number of subjects: 56
Study 21791058 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD + erlotinib (150 mg QD)
Number of subjects: 56
Study 21791058 — intervention group
Group type: COMPARATOR
Intervention: Motesanib (50 mg QD, 75 mg BID, 125 mg QD, or 100 mg QD) + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Number of subjects: 56
Study 21791058 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg QD) + motesanib (100 or 125 mg QD)
Number of subjects: 56
Study 21791415 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) in reduced-intensity conditioning
Number of subjects: 206
Study 21791415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ScGVHD
Number of subjects: 206
Study 21791415 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater body surface area involvement in patients with ScGVHD
Number of subjects: 206
Study 21791415 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count and C3 levels in patients with ScGVHD
Number of subjects: 206
Study 21791415 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced vital capacity in patients with ScGVHD
Number of subjects: 206
Study 21791424 — intervention group
Group type: EXPERIMENTAL
Intervention: Global chronic GVHD severity (mild, moderate, severe) at enrollment
Number of subjects: 298
Study 21791424 — intervention group
Group type: EXPERIMENTAL
Intervention: Global severity scores at enrollment
Number of subjects: 298
Study 21791424 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year overall survival based on global severity scores
Number of subjects: 298
Study 21791425 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of highly purified CD56(+)CD3(-) natural killer (NK) cells from haploidentical donors after fludarabine/cyclophosphamide immunosuppressive chemotherapy, followed by IL-2; median number of infused NK cells was 2.74 × 10(6)/Kg; T cells were < 10(5)/Kg.
Number of subjects: 13
Study 21791469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib treatment
Number of subjects: 469
Study 21791473 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 15 mg/kg bid
Number of subjects: 6
Study 21791475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 400 mg/m(2)/day for 5 days + Tanespimycin 300 mg/m(2) on days 3 and 6
Number of subjects: 26
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antiplatelet therapy (OAT) interruption for more than 5 days prior to surgery
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative haemoglobin <10 g/dl
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance <30 ml/min
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency or high-risk surgery
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance between 30 and 60 ml/min
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay from stent implantation to surgery <3 months
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk surgery according to the Lee classification
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of MACCE
Number of subjects: 1134
Study 21791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of major bleeding complications
Number of subjects: 1134
Study 21791540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 186
Study 21791540 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 186
Study 21791540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL and BNP combination
Number of subjects: 186
Study 21791540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL and BNP elevated
Number of subjects: 186
Study 21791540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BNP and high NGAL
Number of subjects: 186
Study 21791540 — intervention group
Group type: COMPARATOR
Intervention: Serum creatinine and eGFR
Number of subjects: 186
Study 21791546 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 48
Study 21791546 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 48
Study 21791546 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) and Etanercept (ETA)
Number of subjects: 48
Study 21791591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrus OCT system
Number of subjects: 112
Study 21791591 — intervention group
Group type: COMPARATOR
Intervention: Spectralis OCT system
Number of subjects: 112
Study 21791687 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of sentinel lymph nodes (SLNs) for tumor detection
Number of subjects: 5210
Study 21791687 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemical staining of bone marrow for tumor detection
Number of subjects: 5210
Study 21794112 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a multi-country prospective observational study (GRACE-01)
Number of subjects: 0
Study 21794112 — intervention group
Group type: EXPERIMENTAL
Intervention: Solutions implemented in the study
Number of subjects: 0
Study 21794906 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Allergy Herbal Formula-2 (FAHF-2), 3.3 g (6 tablets) three times a day for 6 months
Number of subjects: 18
Study 21794906 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Allergy Herbal Formula-2 (FAHF-2)
Number of subjects: 18
Study 21795476 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan (0.6 mg/m²/d) on days one to five of 21-day cycles
Number of subjects: 24
Study 21795476 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan
Number of subjects: 24
Study 21796719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 205
Study 21796719 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 205
Study 21797863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium
Number of subjects: 656
Study 21798054 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 120
Study 21798965 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary lateral sclerosis
Number of subjects: 56
Study 21798965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyotrophic lateral sclerosis
Number of subjects: 56
Study 21798965 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 56
Study 21798965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 56
Study 21799175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet or gastric surgery
Number of subjects: 0
Study 21799479 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels (ng/ml)
Number of subjects: 80
Study 21799479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration and sleep efficiency measured by 2 weeks of wrist actigraphy
Number of subjects: 80
Study 21799479 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory disturbance index (RDI) assessed by a portable screening device
Number of subjects: 80
Study 21799809 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1/C1-Alhydrogel+CPG 7909
Number of subjects: 8
Study 21799809 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 8
Study 21799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in patients with type 3 Gaucher disease
Number of subjects: 15
Study 21799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal saccades
Number of subjects: 15
Study 21799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward saccades
Number of subjects: 15
Study 21799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculo-manual dexterity scores on the Purdue Pegboard test
Number of subjects: 15
Study 21799847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical saccade peak duration vs amplitude slope
Number of subjects: 15
Study 21801387 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose regulation diagnosed in-hospital (n = 105, 47%)
Number of subjects: 224
Study 21801387 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose regulation diagnosed at three-month follow-up (n = 50, 25%)
Number of subjects: 224
Study 21801387 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analysis of survival free of composite end-points
Number of subjects: 224
Study 21801387 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical events during follow-up
Number of subjects: 224
Study 21801411 — intervention group
Group type: EXPERIMENTAL
Intervention: Project FIT intervention (multi-faceted approach including school, community, social marketing, and school staff wellness)
Number of subjects: 403
Study 21801604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix vaccine (three doses in Months 0, 1, and 6)
Number of subjects: 30
Study 21801604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Number of subjects: 30
Study 21801857 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel
Number of subjects: 0
Study 21801857 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 21802835 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg daily and continuously
Number of subjects: 41
Study 21802835 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPRSS2-ERG status
Number of subjects: 41
Study 21802881 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring using Nexfin finger cuff technology
Number of subjects: 40
Study 21802881 — intervention group
Group type: COMPARATOR
Intervention: Intermittent monitoring using standard automated ED devices
Number of subjects: 40
Study 21802924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro-alcoholic extract of Lippia alba leaves, administered orally for 30-60 days.
Number of subjects: 0